SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2431989459> ?p ?o ?g. }

Showing items 1 to 100 of ±166 with 100 items per page.

W2431989459 endingPage "76" @default.
W2431989459 startingPage "69" @default.
W2431989459 abstract "For patients with coronary artery disease undergoing coronary bypass surgery, acetylsalicylic acid (ASA) currently represents the gold standard of antiplatelet treatment. However, adverse cardiovascular event rates in the first year after coronary artery bypass grafting (CABG) still exceed 10%. Graft failure, which is predominantly mediated by platelet aggregation, has been identified as a major contributing factor in this context. Therefore, intensified platelet inhibition is likely to be beneficial. Ticagrelor, an oral, reversibly binding and direct-acting P2Y12 receptor antagonist, provides a rapid, competent, and consistent platelet inhibition and has shown beneficial results compared with clopidogrel in the subset of patients undergoing bypass surgery in a large previous trial.Ticagrelor is superior to ASA for the prevention of major cardiovascular events within 1 year after CABG.The TiCAB trial (NCT01755520) is a multicenter, phase III, double-blind, double-dummy, randomized trial comparing ticagrelor with ASA for the prevention of major cardiovascular events within 12 months after CABG. Patients undergoing CABG will be randomized in a 1:1 fashion to either ticagrelor 90 mg twice daily or ASA 100 mg once daily. The study medication will be started within 24 hours after surgery and maintained for 12 months. The primary end point is the composite of cardiovascular death, myocardial infarction, stroke, and repeat revascularization at 12 months after CABG. The sample size is based on an expected event rate of 13% of the primary end point within the first 12 months after randomization in the control group, a 2-sided α level of .0492 (to preserve the overall significance level of .05 after planned interim analysis), a power of 0.80%, 2-sided testing, and an expected relative risk of 0.775 in the active group compared with the control group and a dropout rate of 2%. According to power calculations based on a superiority design for ticagrelor, it is estimated that 3,850 patients should be enrolled.There is clinical equipoise on the issue of optimal platelet inhibition after CABG. The TiCAB trial will provide a pivotal comparison of the efficacy and safety of ticagrelor compared with ASA after CABG." @default.
W2431989459 created "2016-06-24" @default.
W2431989459 creator A5000925780 @default.
W2431989459 creator A5004375284 @default.
W2431989459 creator A5006513598 @default.
W2431989459 creator A5006952690 @default.
W2431989459 creator A5009463511 @default.
W2431989459 creator A5010936003 @default.
W2431989459 creator A5015669756 @default.
W2431989459 creator A5027165792 @default.
W2431989459 creator A5029161474 @default.
W2431989459 creator A5030020298 @default.
W2431989459 creator A5032543068 @default.
W2431989459 creator A5035585331 @default.
W2431989459 creator A5036070746 @default.
W2431989459 creator A5036203401 @default.
W2431989459 creator A5041871322 @default.
W2431989459 creator A5042165645 @default.
W2431989459 creator A5042795574 @default.
W2431989459 creator A5042925324 @default.
W2431989459 creator A5045450571 @default.
W2431989459 creator A5052207475 @default.
W2431989459 creator A5061879992 @default.
W2431989459 creator A5064315014 @default.
W2431989459 creator A5069862470 @default.
W2431989459 creator A5070353787 @default.
W2431989459 creator A5070822264 @default.
W2431989459 creator A5073088808 @default.
W2431989459 creator A5073906687 @default.
W2431989459 creator A5076258810 @default.
W2431989459 creator A5079886562 @default.
W2431989459 creator A5080844903 @default.
W2431989459 creator A5085742591 @default.
W2431989459 creator A5085798844 @default.
W2431989459 creator A5086668620 @default.
W2431989459 creator A5087441114 @default.
W2431989459 date "2016-09-01" @default.
W2431989459 modified "2023-10-18" @default.
W2431989459 title "A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial" @default.
W2431989459 cites W136622145 @default.
W2431989459 cites W1930503019 @default.
W2431989459 cites W1981694432 @default.
W2431989459 cites W1990632885 @default.
W2431989459 cites W1998869090 @default.
W2431989459 cites W2019909594 @default.
W2431989459 cites W2102860654 @default.
W2431989459 cites W2105397247 @default.
W2431989459 cites W2122779695 @default.
W2431989459 cites W2135164162 @default.
W2431989459 cites W2138512778 @default.
W2431989459 cites W2140501627 @default.
W2431989459 cites W2140991303 @default.
W2431989459 cites W2148737731 @default.
W2431989459 cites W2156255513 @default.
W2431989459 cites W2161055506 @default.
W2431989459 cites W2163050713 @default.
W2431989459 cites W2221460676 @default.
W2431989459 cites W2616651817 @default.
W2431989459 cites W4252254189 @default.
W2431989459 doi "https://doi.org/10.1016/j.ahj.2016.05.017" @default.
W2431989459 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27595681" @default.
W2431989459 hasPublicationYear "2016" @default.
W2431989459 type Work @default.
W2431989459 sameAs 2431989459 @default.
W2431989459 citedByCount "18" @default.
W2431989459 countsByYear W24319894592017 @default.
W2431989459 countsByYear W24319894592018 @default.
W2431989459 countsByYear W24319894592019 @default.
W2431989459 countsByYear W24319894592020 @default.
W2431989459 countsByYear W24319894592021 @default.
W2431989459 countsByYear W24319894592022 @default.
W2431989459 countsByYear W24319894592023 @default.
W2431989459 crossrefType "journal-article" @default.
W2431989459 hasAuthorship W2431989459A5000925780 @default.
W2431989459 hasAuthorship W2431989459A5004375284 @default.
W2431989459 hasAuthorship W2431989459A5006513598 @default.
W2431989459 hasAuthorship W2431989459A5006952690 @default.
W2431989459 hasAuthorship W2431989459A5009463511 @default.
W2431989459 hasAuthorship W2431989459A5010936003 @default.
W2431989459 hasAuthorship W2431989459A5015669756 @default.
W2431989459 hasAuthorship W2431989459A5027165792 @default.
W2431989459 hasAuthorship W2431989459A5029161474 @default.
W2431989459 hasAuthorship W2431989459A5030020298 @default.
W2431989459 hasAuthorship W2431989459A5032543068 @default.
W2431989459 hasAuthorship W2431989459A5035585331 @default.
W2431989459 hasAuthorship W2431989459A5036070746 @default.
W2431989459 hasAuthorship W2431989459A5036203401 @default.
W2431989459 hasAuthorship W2431989459A5041871322 @default.
W2431989459 hasAuthorship W2431989459A5042165645 @default.
W2431989459 hasAuthorship W2431989459A5042795574 @default.
W2431989459 hasAuthorship W2431989459A5042925324 @default.
W2431989459 hasAuthorship W2431989459A5045450571 @default.
W2431989459 hasAuthorship W2431989459A5052207475 @default.
W2431989459 hasAuthorship W2431989459A5061879992 @default.
W2431989459 hasAuthorship W2431989459A5064315014 @default.
W2431989459 hasAuthorship W2431989459A5069862470 @default.
W2431989459 hasAuthorship W2431989459A5070353787 @default.
W2431989459 hasAuthorship W2431989459A5070822264 @default.